Image showing two insulin FlexTouch® pens: the top pen is labeled Tresiba® (insulin degludec injection) with a green dosage selector, and the bottom pen is labeled Fiasp® (insulin aspart injection) with a red dosage selector, both designed for single-patient use.

Novo Nordisk plans to reduce U.S. list prices for its insulin products, Tresiba® and Fiasp®, by over 70% starting January 1, 2026. This move aims to improve insulin affordability and streamline product offerings.

jcst2d.com/index.php?vi...

#NovoNordisk #InsulinPrices #DiabetesCare #Tresiba #Fiasp